CR9135A - Derivados novedosos pirrolidilo de compuestos heteroaromaticos - Google Patents

Derivados novedosos pirrolidilo de compuestos heteroaromaticos

Info

Publication number
CR9135A
CR9135A CR9135A CR9135A CR9135A CR 9135 A CR9135 A CR 9135A CR 9135 A CR9135 A CR 9135A CR 9135 A CR9135 A CR 9135A CR 9135 A CR9135 A CR 9135A
Authority
CR
Costa Rica
Prior art keywords
compounds
derivatives
pirrolidile
novedous
heteroaromatic compounds
Prior art date
Application number
CR9135A
Other languages
English (en)
Inventor
Allen Chappie Thomas
Michael Humphrey John
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR9135A publication Critical patent/CR9135A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a nuevos derivados pirrolidilo de compuestos heteroaromaticos aza benzo- condensados que sirven como inhibidores eficaces de la fosfodiesterasa (PDE).La invencion tambien se refiere a compuestos que son inhibidores selectivos de la PDE-10. La invencion se refiere adicionalmente a intermedios para la preparacion de tales compuestos, composiciones farmaceuticas que comprenden tales compuestos y el uso de tales compuestos en procedimientos para tratar ciertos transtornos del sistema nervioso central (SNC) u otros
CR9135A 2004-12-31 2007-05-18 Derivados novedosos pirrolidilo de compuestos heteroaromaticos CR9135A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64040504P 2004-12-31 2004-12-31

Publications (1)

Publication Number Publication Date
CR9135A true CR9135A (es) 2007-08-14

Family

ID=36046318

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9135A CR9135A (es) 2004-12-31 2007-05-18 Derivados novedosos pirrolidilo de compuestos heteroaromaticos

Country Status (23)

Country Link
US (1) US20060183763A1 (es)
EP (1) EP1838702A1 (es)
JP (1) JP2008526726A (es)
KR (1) KR20070086841A (es)
CN (1) CN101087778A (es)
AP (1) AP2007004004A0 (es)
AR (1) AR055298A1 (es)
AU (1) AU2005321015A1 (es)
BR (1) BRPI0519760A2 (es)
CA (1) CA2594251A1 (es)
CR (1) CR9135A (es)
EA (1) EA200701118A1 (es)
GT (1) GT200500367A (es)
IL (1) IL183188A0 (es)
MA (1) MA29119B1 (es)
MX (1) MX2007006301A (es)
NL (1) NL1030819C2 (es)
NO (1) NO20073958L (es)
PE (1) PE20060775A1 (es)
TN (1) TNSN07248A1 (es)
TW (1) TW200637851A (es)
UY (1) UY29317A1 (es)
WO (1) WO2006070284A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531709A (ja) * 2005-03-01 2008-08-14 ワイス シンノリン化合物および肝臓ｘ受容体調節物質としてのそれらの使用
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
CA2635439A1 (en) * 2006-01-27 2007-08-02 Pfizer Products Inc. Aminophthalazine derivative compounds
US20070265270A1 (en) * 2006-02-21 2007-11-15 Hitchcock Stephen A Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2007217750A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
US20070287707A1 (en) * 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
JP2009529060A (ja) * 2006-03-08 2009-08-13 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのキノリン及びイソキノリン誘導体
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
BRPI0811745B1 (pt) * 2007-05-17 2019-06-04 Helperby Therapeutics Limited Compostos de 4-(pirrolidin-1-il)quinolina, uso e processo para a preparação dos mesmos, formulação farmacêutica --
UA102693C2 (ru) * 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI396689B (zh) * 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
KR20160105948A (ko) * 2010-11-08 2016-09-07 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
RS58381B1 (sr) * 2012-05-07 2019-04-30 Omeros Corp Lečenje zavisnosti i poremećaja kontrole impulsa upotrebom pde7 inhibitora
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
ITVI20130032A1 (it) * 2013-02-14 2014-08-15 F I S Fabbrica Italiana Sint I S P A Procedimento per la preparazione di n-boc-pirrolidinone
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
TW201611834A (en) * 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
CA2943011A1 (en) * 2014-04-04 2015-10-08 H. Lundbeck A/S Halogenated quinazolin-thf-amines as pde1 inhibitors
AU2016210544B2 (en) * 2015-01-23 2020-12-10 Gvk Biosciences Private Limited Inhibitors of TrkA kinase
SMT202200465T1 (it) 2016-07-14 2023-01-13 Crinetics Pharmaceuticals Inc Modulatori della somatostatina e loro usi
CN106632089B (zh) * 2016-11-04 2019-06-18 中山大学 一类喹唑啉类化合物及其制备方法与应用
CA3091555A1 (en) * 2017-12-26 2019-07-04 Mediconns (Shanghai) Biopharmaceutical Co., Ltd Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
CN116456968B (zh) 2020-09-09 2026-03-20 克林提克斯医药股份有限公司 生长抑素调节剂的制剂
CN115417802A (zh) * 2021-05-16 2022-12-02 上海鼎雅药物化学科技有限公司 乌帕替尼及其中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577432A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
JP3919272B2 (ja) * 1996-12-18 2007-05-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナゾリン系化合物
PT1107965E (pt) * 1998-08-25 2004-10-29 Ortho Mcneil Pharm Inc Eteres e tioeteres de piridilo como ligantes para receptores de acetilcolina nicotinica e as suas aplicacoes terapeuticas
US20020151712A1 (en) * 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
AU2002338896B2 (en) * 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US20070021404A1 (en) * 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1755611A1 (en) * 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions

Also Published As

Publication number Publication date
PE20060775A1 (es) 2006-09-01
MX2007006301A (es) 2007-06-15
EA200701118A1 (ru) 2007-12-28
AU2005321015A1 (en) 2006-07-06
TW200637851A (en) 2006-11-01
KR20070086841A (ko) 2007-08-27
NO20073958L (no) 2007-09-27
IL183188A0 (en) 2007-08-19
CN101087778A (zh) 2007-12-12
UY29317A1 (es) 2006-07-31
CA2594251A1 (en) 2006-07-06
NL1030819C2 (nl) 2007-01-04
EP1838702A1 (en) 2007-10-03
JP2008526726A (ja) 2008-07-24
TNSN07248A1 (fr) 2008-11-21
MA29119B1 (fr) 2007-12-03
US20060183763A1 (en) 2006-08-17
BRPI0519760A2 (pt) 2009-03-10
AR055298A1 (es) 2007-08-15
NL1030819A1 (nl) 2006-07-03
GT200500367A (es) 2006-08-16
AP2007004004A0 (en) 2007-06-30
WO2006070284A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
CR9135A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
GT200600002A (es) Compuestos de quinolina heteroaromaticos
PA8624101A1 (es) Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina
ECSP077193A (es) Nuevos derivados piperidilo de quinazolina e isoquinolina
CR9834A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
UY30080A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
UY28876A1 (es) Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central
DK1377586T3 (da) Tricykliske diazepiner som tocolytiske oxytocinreceptorantagonister
GT200500332A (es) Azabenzoxazoles para el tratamiento de trastornos del snc
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
CR7735A (es) Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia
UY29052A1 (es) Nuevos inhibidores de la recaptación de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central
DOP2005000139A (es) Nuevos derivados piperidilo do quinazolina e isoquinolina
DOP2005000273A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
DOP2006000004A (es) Compuestos de quinolina heteroaromaticos.
UY28476A1 (es) (1,8) naftirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
DOP2005000151A (es) Nuevos inhibidores de la recaptacion de norepinefrina de quinoxalinona para el tratamiento de trastonos del sisitema nervioso central.
DOP2004000837A (es) Inhibidores de p38 y metodos de uso de ellos (p38 inhibitors and methods of use thereof)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)